HSPA13

Across TCGA pan-cancer cohorts, HSPA13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HSPA13 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HSPA13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSPA13 expression acts as an unfavorable survival marker.

CCRCC, UCEC, and PDAC are the cancer types where HSPA13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.320	0.833	.001	41	view →
UCEC	DFS	Median	All	0.850	0.952	.015	14	view →
PDAC	DFS	Tertile	All	0.226	0.437	.022	8	view →
LSCC	DFS	Quartile	II,III,IV	0.828	1.000	.028	3	view →
LUAD	OS	Quartile	III,IV	0.827	1.000	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HSPA13–CCRCC (DFS)

Open the CCRCC breakdown →